The error bars show the mean and standard deviation. patients than CGS19755 in HDs. The serum antibody levels to these antigens were also elevated in PAH patients. The titers against EXD2 peptide decreased after surgical treatment in CTEPH patients. These autoantibodies may be useful as biomarkers of CTEPH and PAH, and further investigations may provide novel insight into the etiology. == Introduction == Chronic thromboembolic pulmonary hypertension (CTEPH) is a form of pulmonary hypertension (PH) caused by persistent thromboemboli of the pulmonary arteries. Various etiological factors, including infection, inflammation, genetic susceptibilities, and insufficient angiogenesis [1], have been discussed as important pathogenetic factors [2]. However, the etiology of CTEPH is not completely understood, and disease-specific, non-invasive biomarkers have not been identified. Circulating autoantibodies have been detected in patients with several cardiovascular diseases, such as atherosclerosis [3,4] and other cardiovascular diseases, including coronary artery diseases[5]. As a typical example, anti-phospholipid antibodies reportedly enhance the uptake of oxidized LDL by macrophages, which leads to foam cell formation [57]. Recently, we established the auto-antibody screening method using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) and found that anti-adiponectin antibody levels were significantly higher in patients with coronary artery disease, cerebral infarction and diabetes mellitus than in HDs [8]. However, autoantibodies in the context of CTEPH and pulmonary arterial hypertension (PAH) have not yet been thoroughly explored. In the present study, we comprehensively screened autoantigens recognized by IgG antibodies TMOD3 in the sera of patients with CTEPH using a protein array. We then selected and identified the autoantibodies elevated in the CGS19755 sera of CTEPH patients and also investigated whether or not PAH patients had the same autoantibodies. == Materials and methods == == Ethical statement == The protocol for the analysis of the sera from CTEPH and PAH CGS19755 patients was approved by the Local Ethical Review Board of the Chiba University Graduate School of Medicine (approval number 1248). The protocol for the serum analysis in healthy donors (HDs) and the patients with sleep apnea syndrome (SAS) was also approved by the Local Ethical Review Board of the Chiba University Graduate School of Medicine (approval number 973). Written informed consent was obtained from all participating patients before sera were collected. == Patients and healthy donor sera == We collected serum samples from patients diagnosed with CTEPH and PAH at Chiba University Hospital between 2001 and 2015. Serum samples were collected from HDs who underwent annual medical checkups at Port Square Kashiwado Clinic. We also collected serum samples from patients with SAS, as previously reported [9] [10]. Each serum sample was centrifuged at 3,000 gfor 10 min at room temperature, and then the supernatant was stored at -80C until use (no CGS19755 other freeze-thaw cycles). == The ProtoArray human protein microarrays analysis == Serum samples from 5 CTEPH patients and 5 HDs were profiled on a ProtoArray Human Protein Microarrays v5.1 containing 9,375 human proteins. The serum samples were profiled at a 1:500 dilution, utilizing one ProtoArray Human being Protein Microarray per sample. Alexa Fluor 647-anti-human IgG detection reagent was used to quantify the IgG level of connected auto-antibodies. Pairwise comparisons were made between the two sample populations. Assays were performed by Thermo Fisher Scientific (Waltham, MA, USA) according to the manufacturers instructions. == Epitope prediction and peptide synthesis == Possible epitope sites in the selected antigenic proteins were predicted using the software system ProPred (http://www.imtech.res.in/raghava/propred/) mainly because described previously [11]. == Amplified luminescence proximity homogeneous assay (AlphaLISA) == AlphaLISA was performed in 384-well microtiter plates (white opaque ProxiPlate PerkinElmer, Waltham, MA, USA) comprising 2.5 L of 1/100-diluted sera and 2.5 L of GST or a GST-fusion protein (10 g/mL) in AlphaLISA buffer (25 mM 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid [HEPES], pH 7.4, 0.1% casein, 0.5% Triton X-100, 1 mg/mL dextran-500, and 0.05% Proclin-300). The producing reaction combination was incubated at space temperature for 6 to 8 8 h. After incubation, anti-human IgG-conjugated acceptor beads (2.5 L of 40 g/mL) and streptavidin-conjugated donor beads (2.5 L of 40 g/mL) were added, and the samples were subjected to an additional 7 to 21 days of incubation at room temperature in the dark. The chemical emissions of samples were read on an EnSpire Alpha microplate reader (PerkinElmer). Specific reactions were determined by subtracting the alpha ideals of buffer control samples from those of samples comprising biotinylated peptides. The details have been.
